Feature

How Clinicians Can Help Patients Navigate Psychedelics/Microdosing


 

Navigating Legality

Recent ballot measures in Oregon and Colorado directed the states to develop regulated and licensed psilocybin-assisted therapy centers for legal “trips.” Oregon’s first center was opened in 2023, and Colorado is now developing its own licensing model.

According to the Oregon Health Authority, the centers are not medical facilities, and prescription or referral from a medical professional is not required.

The Oregon Academy of Family Physicians (OAFP) has yet to release guidance to clinicians on how to talk to their patients about these drugs or potential interest in visiting a licensed therapy center.

However, Betsy Boyd-Flynn, executive director of OAFP, said the organization is working on continuing medical education for what the average family physician needs to know if a patient asks about use.

“We suspect that many of our members have interest and want to learn more,” she said.

Dr. Grinspoon said clinicians should talk with patients about legality during these conversations.

“The big question I get is: ‘I really want to try microdosing, but how do I obtain the mushrooms?’ ” he said. “You can’t really as a physician tell them to do anything illegal. So you tell them to be safe, be careful, and to use their judgment.”

Patients who want to pursue microdosing who do not live in Oregon have two legal and safe options, Dr. Grinspoon said: Enroll in a clinical study or find a facility in a state or country — such as Oregon or Jamaica — that offers microdosing with psilocybin.

Clinicians also should warn their patients that the consequences of obtaining illicit psilocybin could exacerbate the mental health stresses they are seeking to alleviate.

“It’s going to get worse if they get tangled up with law enforcement or take something that’s contaminated and they get real sick,” he said.

Lisa Gillespie contributed reporting to this story. A version of this article appeared on Medscape.com.

Pages

Recommended Reading

New Models Predict Time From Mild Cognitive Impairment to Dementia
MDedge Internal Medicine
Undiagnosed, Untreated Tardive Dyskinesia, Hinders Adherence to Antipsychotics
MDedge Internal Medicine
Alzheimer’s Blood Test in Primary Care Could Slash Diagnostic, Treatment Wait Times
MDedge Internal Medicine
‘Psychological Weight’ Crucial in Patients With Obesity
MDedge Internal Medicine
When Is Sexual Behavior Out of Control?
MDedge Internal Medicine
Psychiatric, Autoimmune Comorbidities Increased in Patients with Alopecia Areata
MDedge Internal Medicine
An Effective Nondrug Approach to Improve Sleep in Dementia, Phase 3 Data Show
MDedge Internal Medicine
Cognitive Breakdown: The New Memory Condition Primary Care Needs to Know
MDedge Internal Medicine
Electroconvulsive Therapy Works, Now Scientists Believe They Know How
MDedge Internal Medicine
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
MDedge Internal Medicine